Why Personalis is one of the most innovative biotech companies of 2024
Through genomic sequencing and analytics, Sacramento-based Personalis aims to make detection of cancer ever more precise and timely. In October 2023, the company launched early access to its NeXT Personal Dx test, which offers ultra-sensitive circulating tumor DNA (ctDNA) detection, enabling earlier detection of cancer recurrence and more detailed monitoring of treatment response. NeXT Personal Dx is a whole-genome sequencing test that detects circulating tumor DNA molecules, finding previously hidden traces of residual…